Further to the ongoing clinical programs, in our preclinical research we are investigating the use of our technology platform as a pre-treatment in gene therapy, as well as developing our next generation enzyme for repeat dosing.
We are exploring opportunities for imlifidase to potentially enable gene therapy treatment in patients with pre-existing neutralizing antibodies (Nabs), against adeno-associated viral vectors, or AAVs. We have established collaboration with: Sarepta to assess imlifidase as a pre-treatment in Limb-Girdle Muscular Dystrophy, or LGMD, and Duchenne Muscular Dystrophy, or DMD; AskBio to evaluate imlifidase as a pre-treatment in Pompe disease; and with Généthon to evaluate imlifidase as a pre-treatment prior to the administration of gene therapy in Crigler-Najjar syndrome.
Beyond imlifidase, we are advancing our enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing, known as the NiceR (Novel Immunoglobulin Cleaving Enzymes for Repeat dosing) program. The next generation of IgG-cleaving enzymes could enable new opportunities in a range of potential indications including relapsing autoimmune diseases and gene therapy, as well as oncology.
Investigator sponsored trials
At Hansa Biopharma, we believe in the need to support ethical independent clinical research conducted by qualified third-party investigators. Investigators are encouraged to create studies (i.e. investigator sponsored trials or ISTs) and submit these study concepts to Hansa Biopharma.